• Je něco špatně v tomto záznamu ?

Oral administration of BDNF and/or GDNF normalizes serum BDNF level in the olfactory bulbectomized rats: A proof of concept study

J. Kucera, J. Ruda-Kucerova, F. Zlamal, D. Kuruczova, Z. Babinska, J. Tomandl, M. Tomandlova, J. Bienertova-Vasku,

. 2019 ; 71 (4) : 669-675. [pub] 20190316

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006262

BACKGROUND: Neurotrophins, especially brain-derived neurotrophic factor (BDNF) have gained significant therapeutic interest particularly in neurologic and psychiatric disorders and they have been found in human breast milk of mothers who suffered from adverse outcomes in pregnancy. This study tested the hypothesis that oral administration of BDNF/GDNF (glial cell line-derived neurotrophic factor) can exert a biological effect in a rat model of severe neuropathology induced by olfactory bulbectomy (OBX), which exhibits dysregulation of BDNF signaling and impaired blood-brain barrier. METHODS: Adult male albino Sprague-Dawley rats underwent the OBX surgery and separate groups of OBX and sham-operated controls received one oral dose of vehicle, BDNF (0.005 mg/kg), GDNF (0.03 mg/kg) or their combination. One week after neurotrophin dosing the rats were sacrificed and BDNF level was assessed by ELISA in the blood serum and cerebrospinal fluid. RESULTS: A significant decrease of serum BDNF level was found in the OBX model. This alteration was normalized by all types of treatment BDNF, GDNF, or their combination. No influence of sham surgery or treatment was observed in the control rats. BDNF levels in cerebrospinal fluid were below detection limit. CONCLUSION: This study indicates that oral administration of neurotrophins is able to exert a biological effect in the OBX model. There is a number of potential mechanisms, which remain to be elucidated.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006262
003      
CZ-PrNML
005      
20200526105346.0
007      
ta
008      
200511s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.pharep.2019.03.005 $2 doi
035    __
$a (PubMed)31195344
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kucera, Jan $u RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
245    10
$a Oral administration of BDNF and/or GDNF normalizes serum BDNF level in the olfactory bulbectomized rats: A proof of concept study / $c J. Kucera, J. Ruda-Kucerova, F. Zlamal, D. Kuruczova, Z. Babinska, J. Tomandl, M. Tomandlova, J. Bienertova-Vasku,
520    9_
$a BACKGROUND: Neurotrophins, especially brain-derived neurotrophic factor (BDNF) have gained significant therapeutic interest particularly in neurologic and psychiatric disorders and they have been found in human breast milk of mothers who suffered from adverse outcomes in pregnancy. This study tested the hypothesis that oral administration of BDNF/GDNF (glial cell line-derived neurotrophic factor) can exert a biological effect in a rat model of severe neuropathology induced by olfactory bulbectomy (OBX), which exhibits dysregulation of BDNF signaling and impaired blood-brain barrier. METHODS: Adult male albino Sprague-Dawley rats underwent the OBX surgery and separate groups of OBX and sham-operated controls received one oral dose of vehicle, BDNF (0.005 mg/kg), GDNF (0.03 mg/kg) or their combination. One week after neurotrophin dosing the rats were sacrificed and BDNF level was assessed by ELISA in the blood serum and cerebrospinal fluid. RESULTS: A significant decrease of serum BDNF level was found in the OBX model. This alteration was normalized by all types of treatment BDNF, GDNF, or their combination. No influence of sham surgery or treatment was observed in the control rats. BDNF levels in cerebrospinal fluid were below detection limit. CONCLUSION: This study indicates that oral administration of neurotrophins is able to exert a biological effect in the OBX model. There is a number of potential mechanisms, which remain to be elucidated.
650    _2
$a aplikace orální $7 D000284
650    _2
$a zvířata $7 D000818
650    _2
$a biologický transport $7 D001692
650    _2
$a hematoencefalická bariéra $x účinky léků $x metabolismus $7 D001812
650    _2
$a nemoci mozku $x krev $7 D001927
650    _2
$a mozkový neurotrofický faktor $x aplikace a dávkování $x krev $x mozkomíšní mok $7 D019208
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a neurotrofní faktory $x aplikace a dávkování $x krev $x mozkomíšní mok $7 D009414
650    _2
$a bulbus olfactorius $x chirurgie $7 D009830
650    _2
$a ověření koncepční studie $7 D000075082
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a rekombinantní proteiny $7 D011994
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Zlamal, Filip $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kuruczova, Daniela $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Babinska, Zuzana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Tomandl, Josef $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Tomandlova, Marie $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Bienertova-Vasku, Julie $u RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: jbienert@med.muni.cz.
773    0_
$w MED00165879 $t Pharmacological reports : PR $x 1734-1140 $g Roč. 71, č. 4 (2019), s. 669-675
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31195344 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526105342 $b ABA008
999    __
$a ok $b bmc $g 1525120 $s 1096318
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 71 $c 4 $d 669-675 $e 20190316 $i 1734-1140 $m Pharmacol. Reports $n Pharmacol. Rep. $x MED00165879
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace